EICHORPublic-registry site landscape for NCT07748624, “A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period”, a VEXAS Syndrome study sponsored by Novartis Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07748624 (registry record) |
| Study title | A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period |
| Official title | VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period |
| Sponsor | Novartis Pharmaceuticals |
| Condition(s) | VEXAS Syndrome |
| Phase | PHASE2 |
| Listed sites | 0 |
| Intervention(s) | Arumakimig, Placebo, Oral glucocorticoids |
Patient-friendly overview of this study: eichor.com/study/NCT07748624.
Eichor generates a preliminary site-risk snapshot for NCT07748624 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
